Background Poly (ADP-ribose) polymerase (PARP) inhibitors have shown efficacy and
acceptable safety in a range of neoplasms, particularly in ovarian cancers. However, some …

Background In recurrent ovarian cancer, poly (ADP-ribose) polymerase (PARP)-inhibiting
agents have transformed the treatment of platinum-sensitive disease. New data support use …

The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was
held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research …

Background Niraparib is an oral poly (adenosine diphosphate [ADP]–ribose) polymerase
(PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We …

Background Most women with newly diagnosed advanced ovarian cancer have a relapse
within 3 years after standard treatment with surgery and platinum-based chemotherapy. The …

Background Niraparib, an inhibitor of poly (adenosine diphosphate [ADP]–ribose)
polymerase (PARP), has been associated with significantly increased progression-free …

Background Olaparib has shown significant clinical benefit as maintenance therapy in
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …

The development of guidelines recommendations is one of the core activities of the
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …

The estimated number of new ovarian cancer cases in Europe in 2012 was 65 538 with 42
704 deaths [1]. There is variation in the incidence rate across the continent with a higher …

Abstract The first joint European Society for Medical Oncology (ESMO), European SocieTy
for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology …